Market Closed -
Nasdaq Stockholm
12:00:00 2024-07-03 pm EDT
|
5-day change
|
1st Jan Change
|
13.45
SEK
|
-0.37%
|
|
-3.24%
|
+79.33%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,578
|
2,173
|
2,277
|
1,987
|
389
|
697.6
|
-
|
-
|
Enterprise Value (EV)
1 |
1,472
|
2,173
|
1,875
|
1,734
|
277.7
|
667.7
|
715.9
|
593.6
|
P/E ratio
|
-15.4
x
|
-21.9
x
|
44
x
|
-17.5
x
|
-2.19
x
|
-7.8
x
|
-47.2
x
|
-6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
60,685
x
|
-
|
11
x
|
32.5
x
|
68.5
x
|
6.53
x
|
3.05
x
|
7.84
x
|
EV / Revenue
|
56,609
x
|
-
|
9.02
x
|
28.4
x
|
48.9
x
|
6.25
x
|
3.13
x
|
6.67
x
|
EV / EBITDA
|
-15.8
x
|
-
|
33.5
x
|
-16
x
|
-1.57
x
|
-8.35
x
|
-105
x
|
-5.3
x
|
EV / FCF
|
-16.1
x
|
-
|
-
|
-
|
-1.68
x
|
-39.3
x
|
4.5
x
|
-5.12
x
|
FCF Yield
|
-6.21%
|
-
|
-
|
-
|
-59.5%
|
-2.55%
|
22.2%
|
-19.5%
|
Price to Book
|
-
|
-
|
-
|
6.83
x
|
-
|
7.23
x
|
2.76
x
|
5.11
x
|
Nbr of stocks (in thousands)
|
43,110
|
51,748
|
51,748
|
51,868
|
51,868
|
51,868
|
-
|
-
|
Reference price
2 |
36.60
|
42.00
|
44.00
|
38.30
|
7.500
|
13.45
|
13.45
|
13.45
|
Announcement Date
|
2/6/20
|
4/15/21
|
2/23/22
|
2/23/23
|
2/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.026
|
-
|
207.8
|
61.14
|
5.678
|
106.8
|
229.1
|
89
|
EBITDA
1 |
-92.92
|
-
|
56.05
|
-108.3
|
-176.4
|
-79.96
|
-6.808
|
-112
|
EBIT
1 |
-95.85
|
-
|
52.58
|
-113.1
|
-180.8
|
-77.06
|
37.48
|
-116
|
Operating Margin
|
-368,646.15%
|
-
|
25.3%
|
-185.01%
|
-3,183.6%
|
-72.18%
|
16.36%
|
-130.34%
|
Earnings before Tax (EBT)
1 |
-96.12
|
-
|
51.78
|
-113.4
|
-177.8
|
-89.5
|
-14.75
|
-116
|
Net income
1 |
-96.12
|
-91.65
|
51.78
|
-113.4
|
-177.8
|
-80.52
|
33.91
|
-116
|
Net margin
|
-369,692.31%
|
-
|
24.92%
|
-185.5%
|
-3,132.07%
|
-75.42%
|
14.81%
|
-130.34%
|
EPS
2 |
-2.370
|
-1.920
|
1.000
|
-2.190
|
-3.430
|
-1.725
|
-0.2850
|
-2.240
|
Free Cash Flow
1 |
-91.34
|
-
|
-
|
-
|
-165.2
|
-17
|
159
|
-116
|
FCF margin
|
-351,300%
|
-
|
-
|
-
|
-2,908.65%
|
-15.92%
|
69.41%
|
-130.34%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
468.82%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/6/20
|
4/15/21
|
2/23/22
|
2/23/23
|
2/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
9.042
|
23.41
|
16.5
|
EBITDA
1 |
-28.14
|
-26.06
|
-22.91
|
EBIT
1 |
-29.09
|
-27.02
|
-23.92
|
Operating Margin
|
-321.7%
|
-115.4%
|
-144.97%
|
Earnings before Tax (EBT)
1 |
-29.17
|
-27.12
|
-23.96
|
Net income
1 |
-29.17
|
-27.12
|
-23.96
|
Net margin
|
-322.61%
|
-115.83%
|
-145.17%
|
EPS
2 |
-0.5600
|
-0.5200
|
-0.4600
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
5/11/22
|
8/24/22
|
11/9/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
18.2
|
-
|
Net Cash position
1 |
106
|
-
|
402
|
253
|
111
|
30
|
-
|
104
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-2.678
x
|
-
|
Free Cash Flow
1 |
-91.3
|
-
|
-
|
-
|
-165
|
-17
|
159
|
-116
|
ROE (net income / shareholders' equity)
|
-48.8%
|
-
|
-
|
-32.9%
|
-
|
-18%
|
89.3%
|
-59.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
5.610
|
-
|
1.860
|
4.870
|
2.630
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.71
|
2.88
|
0.29
|
0.3
|
0.3
|
-
|
Capex / Sales
|
-
|
-
|
0.34%
|
4.7%
|
5.16%
|
0.28%
|
0.13%
|
-
|
Announcement Date
|
2/6/20
|
4/15/21
|
2/23/22
|
2/23/23
|
2/7/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +79.33% | 65.92M | | +54.07% | 816B | | +38.59% | 634B | | -7.05% | 351B | | +15.44% | 323B | | +5.72% | 293B | | +13.40% | 238B | | +0.61% | 222B | | +13.24% | 218B | | +7.42% | 167B |
Other Pharmaceuticals
|